The objective is to compare the costs of providing the same level of quality. When resource-use and quality measures are juxtaposed, the resources used to provide the same level of quality can be compared.
Although not everything on the Choosing Wisely lists is likely to reduce low-value care, it is a good starting point for a conversation about curtailing low-value interventions.
Comparative effectiveness research (CER) may become an important factor in Medicare coverage decisions, and the new health care law may make it more easily available to the public to help in medical decision making.
Despite exclusion of cost from the definition of comparative effectiveness research from the recent health care reform legislation, it will feed into cost-benefit analyses.
The Oxford Centre for Evidence-Based Medicine provides a scale for stratifying evidence from strongest to weakest on the basis of susceptibility to bias and the quality of study design.
Strengthened NIH policies of inclusion have resulted in more NIH-funded research including more women and other underrepresented population groups as subjects in medical research.